# Revolution Medicines, Inc. clinical trials: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with Revolution Medicines, Inc. as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Revolution Medicines, Inc.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 8, 2026 | NCT07805954 | Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic... | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07805954) |
| August 20, 2026 | NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous... | Revolution Medicines, Inc. | Phase 3 | Recruiting | NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC, Non-Squamous Non Small Cell Lung Cancer, Lung... | 430 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777822) |
| June 2, 2026 | NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic... | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 670 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07621718) |
| May 7, 2026 | NCT07573215 | Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma | Revolution Medicines, Inc. | Not applicable | Approved for marketing | PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Metastatic Pancreas Adenocarcinoma, Pancreatic Cancer, Pancreatic Cancer... | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07573215) |
| March 24, 2026 | NCT07491445 | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal... | 900 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07491445) |
| February 9, 2026 | NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumors, Metastatic Solid Tumors, Non-small Cell Lung Cancer (NSCLC), NSCLC, Colorectal Cancer (CRC), CRC | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07397338) |
| January 16, 2026 | NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal... | 574 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349537) |
| November 26, 2025 | NCT07252232 | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC)... | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07252232) |
| March 18, 2025 | NCT06881784 | Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Revolution Medicines, Inc. | Phase 3 | Recruiting | NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC... | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06881784) |
| October 3, 2024 | NCT06625320 | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Revolution Medicines, Inc. | Phase 3 | Active not recruiting | Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06625320) |
| June 6, 2024 | NCT06445062 | Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Colorectal Cancer, CRC, Pancreatic Ductal Adenocarcinoma, PDAC, Gastrointestinal Cancer, Metastatic Pancreatic Ductal... | 1,130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06445062) |
| December 8, 2023 | NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung... | 616 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06162221) |
| November 13, 2023 | NCT06128551 | Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma | 534 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06128551) |
| September 15, 2023 | NCT06040541 | Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid... | 604 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06040541) |
| July 18, 2022 | NCT05462717 | Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Active not recruiting | Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor | 222 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05462717) |
| May 18, 2022 | NCT05379985 | Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Revolution Medicines, Inc. | Phase 1/2 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid... | 754 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05379985) |
| September 23, 2021 | NCT05054725 | Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies | Revolution Medicines, Inc. | Phase 2 | Completed | Non-Small Cell Lung Cancer | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05054725) |
| March 1, 2021 | NCT04774952 | Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Completed | Solid Tumors | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04774952) |
| June 18, 2019 | NCT03989115 | Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC | Revolution Medicines, Inc. | Phase 1/2 | Completed | Solid Tumor | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03989115) |
| August 17, 2018 | NCT03634982 | Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Unknown | Solid Tumors | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03634982) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 6 |
| Phase 2 | 1 |
| Phase 3 | 7 |
| Not applicable | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 13 |
| Completed | 3 |
| Active not recruiting | 2 |
| Unknown | 1 |
| Approved for marketing | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Pancreatic Neoplasms | 13 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Lung Neoplasms | 12 |
| Colorectal Neoplasms | 8 |
| Gastrointestinal Neoplasms | 8 |
| Neoplasms | 7 |
| Bronchial Neoplasms | 6 |
| Respiratory Tract Neoplasms | 6 |
| Thoracic Neoplasms | 6 |
| Neoplasms by Site | 6 |
| Lung Diseases | 6 |
| Respiratory Tract Diseases | 6 |
| Ovarian Neoplasms | 5 |
| Carcinoma, Pancreatic Ductal | 4 |
| Esophageal Neoplasms | 4 |
| Neoplasm Metastasis | 4 |
| Colonic Neoplasms | 4 |
| Melanoma | 3 |
| Skin Neoplasms | 3 |
| Uterine Neoplasms | 3 |
| Urinary Bladder Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Neoplasms, Squamous Cell | 3 |
| Carcinoma, Squamous Cell | 3 |
| Intestinal Neoplasms | 3 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [B2B food products companies in the United States](https://specstream.ai/data/businesses/b2b-food-products-companies/united-states)
- [Industrial equipment manufacturers in the United States](https://specstream.ai/data/businesses/industrial-equipment-manufacturers/united-states)
- [Tree services in the United States](https://specstream.ai/data/businesses/tree-services/united-states)
- [Escrow companies in the United States](https://specstream.ai/data/businesses/escrow-companies/united-states)
- [Pulmonology practices in the United States](https://specstream.ai/data/businesses/pulmonology-practices/united-states)
- [Charter schools in the United States](https://specstream.ai/data/businesses/charter-schools/united-states)
